Crescent Biopharma CBIO Institutional Ownership

Updated Oct 11, 2026

Crescent Biopharma, Inc. (NASDAQ:CBIO) counted 83 institutional investors among its 13F-reported shareholders for the quarter ended June 30, 2026.

• These investors held 96.90% of Crescent Biopharma's outstanding shares at the end of Q2 2026, up from 85.37% in Q1 2026.
• Total shares held in Crescent Biopharma rose 14.02% from Q1 2026, while the number of holders rose 186.21% from Q2 2025.
• Of these 83 holders, 50 added to their positions, 15 reduced their stakes and 18 left their positions unchanged.
• Combined, institutional investors held 29.59Mn shares of CBIO as of Q2 2026, up 3.64Mn from the prior quarter and up 18.85Mn from a year earlier.
• FMR LLC led 13F holders of CBIO with 4.13Mn shares as of June 30, 2026, or 13.54% of shares outstanding.
• Among holders that already owned Crescent Biopharma, the biggest buyers in Q2 2026 were Logos Global Management LP (+1.42Mn shares), BlackRock, Inc. (+1.16Mn shares), Geode Capital Management, LLC (+280.36K shares), State Street Corp (+276.52K shares) and Jennison Associates LLC (+225.53K shares).
• The largest position reductions in CBIO for Q2 2026 were by Silverarc Capital Management, LLC (-71.4K shares), Stonepine Capital Management, LLC (-45K shares), Vanguard Capital Management LLC (-33.64K shares), ADAR1 Capital Management, LLC (-32K shares) and JPMorgan Chase & Co (-31.98K shares).
• Per Business Quant data, the 10 largest holders of Crescent Biopharma at the end of Q2 2026 were FMR LLC (4.13Mn shares), BVF Inc (2.75Mn shares), Fairmount Funds Management LLC (2.75Mn shares), Venrock Adviser, LLC (2.13Mn shares), Logos Global Management LP (1.9Mn shares), FCPM III Services B.V. (1.68Mn shares), Balyasny Asset Management L.P. (1.66Mn shares), Vestal Point Capital, LP (1.63Mn shares), Opaleye Management Inc. (1.32Mn shares) and BlackRock, Inc. (1.27Mn shares).